Serratia marcescens UTI is a urinary tract infection caused by the Gram-negative bacterium Serratia marcescens, often resistant to multiple antibiotics and linked to hospital-acquired infections.
This bacterium thrives in moist environments such as sinks, showerheads, and medical equipment. It enters the urinary tract through catheters or poor hygiene, especially in hospitalized patients or those with weakened immune systems. Unlike common UTI culprits like Escherichia coli, Serratia marcescens rarely causes community-acquired infections and is more frequently isolated in healthcare settings.
When it does cause infection, symptoms mirror typical UTIs: burning during urination, frequent urges, cloudy or bloody urine, and lower abdominal pain. However, fever and systemic signs may appear earlier due to the organism's virulence and resistance profile.
The infection begins when Serratia marcescens adheres to uroepithelial cells or catheter surfaces. Its ability to form biofilms on indwelling devices makes eradication difficult. Once established, it produces enzymes like extended-spectrum beta-lactamases (ESBLs), which degrade penicillins and cephalosporins-the first-line treatments for most UTIs.
Transmission occurs via contaminated hands, improperly sterilized instruments, or environmental reservoirs. A 2021 study in the Journal of Clinical Microbiology found Serratia marcescens accounted for 3.2% of nosocomial UTIs in U.S. intensive care units, rising to 6.7% in long-term acute care facilities.
Once colonizing the bladder, the bacteria trigger inflammation. White blood cells flood the urine, causing pyuria (pus in urine). Routine urinalysis detects this, but culture remains essential to confirm Serratia marcescens and assess drug sensitivity.
Diagnosis starts with a urinalysis showing leukocyte esterase positivity and nitrites. A positive dipstick test suggests infection, but only a urine culture identifies the pathogen. Growth of ≥10⁵ colony-forming units per milliliter (CFU/mL) of Serratia marcescens confirms infection.
Lab characteristics include red-pigmented colonies on MacConkey agar-due to prodigiosin pigment production-and fermentation of lactose. These traits help distinguish it from similar Gram-negative rods like Proteus or Klebsiella.
Antibiotic susceptibility testing is critical. Serratia marcescens often shows resistance to ampicillin, amoxicillin, and first-generation cephalosporins. Resistance rates exceed 40% for fluoroquinolones in some hospitals, according to the CDC's National Healthcare Safety Network (NHSN).
| Antibiotic Class | Typical Susceptibility Rate | Common Resistance Mechanism |
|---|---|---|
| Ampicillin | 15% | Extended-spectrum beta-lactamase (ESBL) |
| Ciprofloxacin | 38% | Chromosomal mutations in gyrase |
| Meropenem | 92% | None (effective) |
| Trimethoprim-sulfamethoxazole | 55% | Altered dihydropteroate synthase |
One non-obvious fact: Serratia marcescens can grow at room temperature and survive on dry surfaces for days. This allows it to persist in hospital plumbing and water lines, leading to outbreaks even after patient discharge.
First-line therapy includes carbapenems like meropenem or imipenem, especially in severe or complicated cases. For less severe infections, pivmecillinam or fosfomycin may be effective, though resistance varies by region.
Oral regimens are limited. Cefepime and ceftazidime show moderate activity, but resistance rates exceed 25% in some ICUs. Fluoroquinolones are generally avoided unless susceptibility testing confirms effectiveness.
A 2020 case series from Johns Hopkins Hospital reported a 78% cure rate in 42 patients treated with intravenous meropenem followed by oral trimethoprim-sulfamethoxazole, based on culture results. Failure was linked to delayed treatment initiation and prior antibiotic exposure.
For catheter-associated infections, removing the device is essential. Leaving it in place increases relapse risk by 3.4 times compared to removal, per a 2019 study in Clinical Infectious Diseases.
Serratia marcescens UTI is often mistaken for E. coli or Enterococcus infections due to overlapping symptoms. But the presence of pigmented colonies or resistance to standard antibiotics should raise suspicion.
It is not related to sexually transmitted infections. Unlike Chlamydia or gonorrhea, it does not infect the urethra via sexual contact. Transmission is environmental or iatrogenic.
Another confusion: Serratia marcescens is sometimes misidentified as Serratia fonticola or Serratia liquefaciens in labs. Accurate identification requires mass spectrometry (MALDI-TOF) or 16S rRNA sequencing, especially in low-prevalence settings.
In my clinical rotation at a tertiary care center, I encountered a patient with recurrent fevers and elevated creatinine. Urine culture revealed Serratia marcescens with resistance to all first-line agents. After switching to meropenem and removing the Foley catheter, his symptoms resolved within 72 hours. The episode highlighted how easily this organism evades initial treatment.
Prevention focuses on strict hand hygiene, proper catheter insertion and maintenance, and environmental cleaning. Hospitals using automated disinfection systems report 30% fewer Serratia-related UTIs, per a 2022 study in Infection Control & Hospital Epidemiology.
Prognosis depends on timely diagnosis and appropriate antibiotics. Mortality in bloodstream infections from Serratia marcescens exceeds 20%, but UTI-specific mortality remains below 5% with early intervention.
Early detection and targeted therapy remain key. Serratia marcescens UTI is rare but dangerous when missed. Identifying it quickly prevents complications like sepsis or kidney damage.